FLASCO hosted the 2025 FLASCO Early Lung Cancer Summit, where we tackled the toughest challenges in lung cancer. This year’s theme, “Challenges in Lung Cancer & The Need For Artificial Intelligence & Blood Biomarkers,” brought together top experts to discuss cutting-edge advancements.
Announcement
Presentations
- “How CT Lung Cancer Screening Became Standard of Care: the ELCAP Story” – Claudia Henschke, PhD, MD
- “Lung Cancer Screening In Non-Smokers & High-Risk Populations” – Alberto Chiappori, MD
- “The Role Of EBUS & Lung Biopsy For Biomarker Testing In The Community & Academic Settings” – Gerard Silvestri, MD, MS
- “How to Complement Biomarker Testing with Diagnostic Imaging” – Catherine R. Sears, MD
- “How to Start a Lung Cancer Screening Program” – Emily Matthews
- “Taking Lung Cancer Screening Program To The Next Level, Do We Need Artificial Intelligence?” – William Mayfield, MD
- “Why IPN Programs Are Needed Now More Than Ever” – Debra S. Dyer, MD, FACR
- “IPN Vs CT Lung Screening – How They Compare” – Raymond Osarogiagbon, MBBS, FACP
- “The Patients Perception Regarding Biomarker Testing & Lung Screening” – Leah Fine
- “Methylation, Circulating Tumor Cells And Exosomes Other Efforts For Early Lung Cancer Detection” – Luis E. Raez, MD, FASCO, FACP
- “The Importance To Use CTDNA To Detect Minimal Residual Disease (MRD)” – Bruna Pellini, MD
